A detailed history of Legal & General Group PLC transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 23,149 shares of TSHA stock, worth $97,457. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,149
Previous 18,395 25.84%
Holding current value
$97,457
Previous $42,000 71.43%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025

BUY
$2.34 - $3.29 $11,124 - $15,640
4,754 Added 25.84%
23,149 $72,000
Q2 2025

Aug 12, 2025

SELL
$1.13 - $2.9 $1,766 - $4,532
-1,563 Reduced 7.83%
18,395 $42,000
Q1 2025

May 15, 2025

SELL
$1.39 - $2.05 $83 - $122
-60 Reduced 0.3%
19,958 $27,000
Q3 2024

Nov 14, 2024

BUY
$2.01 - $2.46 $4,206 - $5,148
2,093 Added 11.68%
20,018 $40,000
Q2 2024

May 29, 2025

SELL
$2.04 - $4.17 $4,147 - $8,477
-2,033 Reduced 10.19%
17,925 $40,000
Q2 2024

Aug 14, 2024

BUY
$2.04 - $4.17 $36,567 - $74,747
17,925 New
17,925 $40,000
Q2 2022

Aug 22, 2022

SELL
$2.47 - $6.77 $39,767 - $108,997
-16,100 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$11.43 - $19.2 $102,789 - $172,665
8,993 Added 126.54%
16,100 $187,000
Q3 2021

Nov 15, 2021

BUY
$15.82 - $21.57 $53,123 - $72,432
3,358 Added 89.57%
7,107 $132,000
Q2 2021

Aug 12, 2021

BUY
$19.29 - $26.38 $54,687 - $74,787
2,835 Added 310.18%
3,749 $80,000
Q4 2020

Feb 12, 2021

BUY
$19.14 - $28.13 $267 - $393
14 Added 1.56%
914 $24,000
Q3 2020

Nov 13, 2020

BUY
$22.4 - $24.47 $20,160 - $22,023
900 New
900 $20,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $204M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.